The Effect of Adding Curcumin to Sertraline in the Treatment of Severe Major Depressive Disorder: A Randomized, Double-Blind Clinical Trial.
Journal
Clinical neuropharmacology
ISSN: 1537-162X
Titre abrégé: Clin Neuropharmacol
Pays: United States
ID NLM: 7607910
Informations de publication
Date de publication:
19 Apr 2023
19 Apr 2023
Historique:
entrez:
18
4
2023
pubmed:
19
4
2023
medline:
19
4
2023
Statut:
aheadofprint
Résumé
Major depressive disorder (MDD) is a chronic and debilitating disease influenced by inflammatory processes in the brain. Some evidence has represented the adding curcumin as a complementary regime to the standard medication in treating depressive symptoms. However, limited clinical trials have been conducted on the antidepressants effects of curcumin in MDD patients. Therefore, this study aimed to investigate the effectiveness of curcumin in the treatment of MDD. In a randomized, double-blind clinical trial, 45 severe MDD patients referred to the psychiatric clinic of Ibn-e-Sina Hospital, Mashhad, Iran, during 2016 were selected. Patients were randomly divided into 2 groups who received sertraline plus curcumin or placebo at a dose of 40 mg/d for 8 weeks. The patients were evaluated using Beck Anxiety and Depression Surveys at the beginning of the study, fourth, and eighth weeks by a psychiatry resident. The data analyzed aiding SPSS software. While depression and anxiety significantly decreased during the 8 weeks of the study, there was no significant difference between the 2 groups (P > 0.05). However, the anxiety score was lower in the intervention group. Moreover, no severe adverse events were observed in all patients. Adding 40 mg/d of SinaCurcumin to sertraline as a routine medical regimen did not improve the depression and anxiety levels in severe MDD patients. However, the anxiety score was lower in the intervention group than in the placebo receiver, which suggests curcumin may have a more effect on anxiety.
Identifiants
pubmed: 37071480
doi: 10.1097/WNF.0000000000000553
pii: 00002826-990000000-00049
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare.
Références
Ferrari AJ, Somerville AJ, Baxter AJ, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med 2013;43(3):471–481.
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392(10159):1789–1858.
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3(11):e442.
Verduijn J, Milaneschi Y, Schoevers RA, et al. Pathophysiology of major depressive disorder: mechanisms involved in etiology are not associated with clinical progression. Transl Psychiatry 2015;5(9):e649.
Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(1):85–102.
Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007;335(7611):142.
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. Am J Psychiatry 2006;163(11):1905–1917.
Verma RK, Kumari P, Maurya RK, et al. Medicinal properties of turmeric (Curcuma longa L.): a review. Int J Chem Stud 2018;6(4):1354–1357.
Ramaholimihaso T, Bouazzaoui F, Kaladjian A. Curcumin in depression: potential mechanisms of action and current evidence-a narrative review. Front Psych 2020;11:57253.
Sarraf P, Parohan M, Javanbakht MH, et al. Short-term curcumin supplementation enhances serum brain-derived neurotrophic factor in adult men and women: a systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Res 2019;69:1–8.
Lopresti AL. Potential role of curcumin for the treatment of major depressive disorder. CNS Drugs 2022;36:123–141.
Seo H-J, Wang S-M, Han C, et al. Curcumin as a putative antidepressant. Expert Rev Neurother 2015;15(3):269–280.
Fusar-Poli L, Vozza L, Gabbiadini A, et al. Curcumin for depression: a meta-analysis. Crit Rev Food Sci Nutr 2020;60(15):2643–2653.
Beck AT, Steer RA, Brown GK. Beck Depression Inventory (BDI-II). London, United Kingdom: Pearson; 1996.
Fata L, Birashk B, Atefvahid M, et al. Meaning assignment structures/schema, emotional states and cognitive processing of emotional information: comparing two conceptual frameworks. Iranian J Psychiatry Clin Psychol 2005;11(3):312–326.
Kaviani H, Mousavi A. Psychometric properties of the Persian version of Beck Anxiety Inventory (BAI). Tehran Univ Med J 2008;66(2):136–140.
Jomehpour H, Aghayan S, Khosravi A, et al. The effect of Krocina™ on decreasing substance user withdrawal syndrome, craving, depression and stress: a double-blind randomized parallel clinical trial. Subst Use Misuse 2022;57:613–620.
Lopresti AL, Drummond PD. Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: a randomised, double-blind, placebo-controlled study. J Affect Disord 2017;207:188–196.
Talaei A, Hassanpour Moghadam M, Sajadi Tabassi SA, et al. Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial. J Affect Disord 2015;174:51–56.
Salek R, Dehghani M, Mohajeri SA, et al. Amelioration of anxiety, depression, and chemotherapy related toxicity after crocin administration during chemotherapy of breast cancer: a double blind, randomized clinical trial. Phytother Res 2021;35(9):5143–5153.
Bergman J, Miodownik C, Bersudsky Y, et al. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. Clin Neuropharmacol 2013;36(3):73–77.
Lopresti AL, Maes M, Maker GL, et al. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J Affect Disord 2014;167:368–375.
Setiawati MC, Ikawati Z, Kertia IN. Antiinflamatory and antidepressive activities of extract Curcuma xanthorrhiza roxb in systemic lupus erythematosus. Indones J Pharm 2017;28(3):185.
Chimakurthy J, Talasila M. Effects of curcumin on pentylenetetrazole-induced anxiety-like behaviors and associated changes in cognition and monoamine levels. Psychol Neurosci 2010;3(2):239–244.
Nouacer M, Bakeche A, Chouba I, et al. Administration of curcumin affects the anxiety behavior in Wistar rats after formaldehyde injected. J Anim Behav Biometeorol 2021;9(3):2127.
Fanaei H, Khayat S, Kasaeian A, et al. Effect of curcumin on serum brain-derived neurotrophic factor levels in women with premenstrual syndrome: a randomized, double-blind, placebo-controlled trial. Neuropeptides 2016;56:25–31.
Asadi S, Gholami MS, Siassi F, et al. Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: a randomized, double-blind, placebo-controlled clinical trial. Phytother Res 2020;34(4):896–903.
Lopresti AL, Smith SJ, Rea A, et al. Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study. BMC Complement Med Ther 2021;21(1):40.
Ma T, Ma Z, Zhang X, et al. Evaluation of effect of curcumin on psychological state of patients with pulmonary hypertension by magnetic resonance image under deep learning. Contrast Media Mol Imaging 2021;2021:1–10.
Esmaily H, Sahebkar A, Iranshahi M, et al. An investigation of the effects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. Chin J Integr Med 2015;21(5):332–338.
Additives EPOF, Food NSAT. Scientific opinion on the re-evaluation of curcumin (E 100) as a food additive. EFSA J 2010;8(9).
Lao CD, Ruffin MT 4th, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006;6(1):10.